Jun 2026 (Q2 FY26) — Jul 29, 2026
Fortive Q2 FY26 — Strong Performance and Raised Full-Year Guidance
Read the full callFortive (FTV) earnings
- Apr 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Fortive earnings: last reported Wed, 29 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 1,069 | +7.7% YoY | Quarterly, as filed | Quarter to Apr 2026 | Revenue from operations as filed. |
| Operating margin | 17.9 | +1.3 pts YoY | Operating profit / revenue | Quarter to Apr 2026 | For the quarter; a change is in percentage points. |
| Net profit | 136 | −20.7% YoY | Quarterly, as filed | Quarter to Apr 2026 | Profit after tax as filed. |
Price
$57.78 +0.94% · +$0.54
Performance +17.8% 1Y
1Y: $49.03 on 14 Oct 2025 → $57.78. High $64.09 (28 Jul 2026), low $48.49 (15 Oct 2025).
- Previous close
- $57.24
- 52-week range
- $48.49 – $64.09
- One year
- +19.16%
Overview
- Symbol
- FTV
- Exchange
- US
- Currency
- USD
Call summaries
Mar 2026 (Q1 FY26) — Apr 30, 2026
Fortive Q1 FY26 — Strong Start with Double-Digit EPS Growth and Accelerated Strategy Traction
Read the full callEvery analysed call
Fortive earnings calls (FTV)
Financials
What the filings say
Net profit, year on year: −21% (quarter to apr 2026 against mar 2025).
| Line item | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,020 | 1,004 | 1,073 | 993 | 1,016 | 1,027 | 1,123 | 1,069 |
| Operating profit | 182 | 172 | 212 | 165 | 170 | 160 | 226 | 192 |
| Operating margin | 17.9% | 17.1% | 19.8% | 16.6% | 16.7% | 15.5% | 20.1% | 17.9% |
| Interest | 39 | 37 | 33 | 32 | 32 | 25 | 31 | 32 |
| Profit before tax | 229 | 109 | 275 | 134 | 192 | 135 | — | 164 |
| Tax rate | 14.7% | −2.2% | 24.0% | 15.8% | 13.2% | 13.3% | — | 16.6% |
| Net profit | 195 | 222 | 209 | 172 | 167 | 55 | 186 | 136 |
| EPS ($ per share) | 0.56 | 0.63 | 0.61 | 0.50 | 0.49 | 0.17 | 0.59 | 0.44 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 |
| Reserves | 3,553 | 4,129 | 5,547 | 6,024 | 6,742 | 7,506 | 8,228 | 5,429 |
| Total liabilities | 6,293 | 10,039 | 7,079 | 6,949 | 6,202 | 6,587 | 6,821 | 5,277 |
| Fixed assets | 396 | 416 | 422 | 396 | 422 | 440 | 233 | 270 |
| Total assets | 12,906 | 17,439 | 16,052 | 16,466 | 15,891 | 16,912 | 17,016 | 11,738 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1,344 | 1,271 | 1,437 | 961 | 1,303 | 1,354 | 1,527 | 1,083 |
| Cash from investing | -1,967 | -4,055 | -148 | -2,616 | -102 | -195 | -1,796 | -135 |
| Cash from financing | 879 | 2,803 | -696 | 652 | -1,273 | 32 | -793 | -1,387 |
| Net cash flow | 216 | 27 | 620 | -1,005 | -110 | 1,180 | -1,075 | -438 |
| Capital expenditure | -70 | -74 | -76 | -50 | -96 | -79 | -86 | -105 |
| Free cash flow | 1,275 | 1,197 | 1,361 | 911 | 1,207 | 1,275 | 1,441 | 978 |
FTV revenue by segment
Intelligent Operating Solutions grew from 43% to 69% of revenue over the last two years.
| Segment | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Intelligent Operating Solutions | 43% | 44% | 46% | 44% | 68% | 583% | 70% | 69% | +12.2% |
| Advanced Healthcare Solutions | 21% | 21% | 21% | 21% | 32% | 254% | 31% | 31% | +6.0% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
FTV operating KPIs by quarter
| KPI | Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|
| Customers | 100KI want to thank our Fortive team members around the world for their commitment to our shared purpose of innovating essential technologies to keep our world safe and productive and 100,000 customers for placing their trust in us every day.Source: earnings call transcript | 100KI mean, we've been really clear in our Fortive Accelerated strategy are the three factors that would drive this company to grow faster, first of those is innovation and new products, second commercial and this recurring cost on value, which means we do more for the 100,000 customers we have that trust us every day.Source: earnings call transcript | 0% |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Revenue by region
Q2 FY2026 · share of revenue
- North America 60%
- Asia Pacific 17%
- EMEA 17%
- Latin America 6%
As FTV cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
43 filings between Oct 31, 2025 and Sep 25, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$6.93M
5 sales by 3 insiders
Compensation
not trading decisions- 20
- Award — granted as compensation
- 3
- Option exercise — converted options into shares
- 11
- Tax withheld — shares kept back by the company to cover tax
Also filed: 4 L filings.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Underwood Peter C | — | $6.41M | Aug 10, 2026 |
| MITCHELL KATE | — | $416.0K | Feb 18, 2026 |
| Walker Stacey A. | — | $110.4K | Oct 31, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 25, 2026 | Lassiter Wright III Director | Code L | 5 | $300 |
| Aug 10, 2026 | Underwood Peter C SVP - Chief Legal Officer | Sale | 8,662 | $533.5K |
| Jul 2, 2026 | Lassiter Wright III Director | Code L | 4 | $257 |
| Jul 2, 2026 | Soroye Olumide President & CEO | Tax withheld | 3,777 | $236.6K |
| Jun 9, 2026 | COMAS DANIEL L Director | Award | 3,350 | $0 |
| Jun 9, 2026 | Desjourdy Amee SVP - Chief People Officer | Award | 5,020 | $0 |
| Jun 9, 2026 | Lassiter Wright III Director | Award | 1,925 | $115.1K |
| Jun 9, 2026 | Sargent Jeannine P Director | Award | 3,350 | $0 |
| Jun 9, 2026 | Dubey Sharmistha Director | Award | 3,305 | $197.6K |
| Jun 9, 2026 | Moore Gregory J. Director | Award | 3,350 | $0 |
| Jun 9, 2026 | Dubey Sharmistha Director | Award | 4,895 | $0 |
| Jun 9, 2026 | Hayes Rejji P Director | Award | 3,350 | $0 |
| Jun 9, 2026 | Hayes Rejji P Director | Award | 2,175 | $130.0K |
| Jun 9, 2026 | Lassiter Wright III Director | Award | 3,350 | $0 |
| Jun 9, 2026 | MITCHELL KATE Director | Award | 3,350 | $0 |
| May 4, 2026 | Underwood Peter C SVP - Chief Legal Officer | Option exercise | 47,557 | $1.38M |
| May 4, 2026 | Underwood Peter C SVP - Chief Legal Officer | Sale | 47,557 | $2.89M |
| Mar 26, 2026 | Lassiter Wright III Director | Code L | 5 | $257 |
| Mar 4, 2026 | Mulhall Christopher M. VP - Chief Accounting Officer | Tax withheld | 446 | $25.9K |
| Mar 4, 2026 | Mulhall Christopher M. VP - Chief Accounting Officer | Tax withheld | 149 | $8.6K |
| Mar 3, 2026 | Mulhall Christopher M. VP - Chief Accounting Officer | Tax withheld | 355 | $20.6K |
| Mar 3, 2026 | Mulhall Christopher M. VP - Chief Accounting Officer | Tax withheld | 933 | $54.1K |
| Mar 2, 2026 | Mulhall Christopher M. VP - Chief Accounting Officer | Award | 9,272 | — |
| Mar 2, 2026 | Mulhall Christopher M. VP - Chief Accounting Officer | Award | 5,839 | — |
| Mar 2, 2026 | Soroye Olumide President & CEO | Award | 68,685 | — |
| Mar 2, 2026 | Desjourdy Amee SVP - Chief People Officer | Award | 44,650 | — |
| Mar 2, 2026 | Okerstrom Mark D SVP - Chief Financial Officer | Award | 41,210 | — |
| Mar 2, 2026 | Underwood Peter C SVP - Chief Legal Officer | Award | 17,175 | — |
| Feb 27, 2026 | Soroye Olumide President & CEO | Tax withheld | 10,940 | $647.6K |
| Feb 27, 2026 | Mulhall Christopher M. VP - Chief Accounting Officer | Tax withheld | 1,021 | $60.4K |
| Feb 27, 2026 | Mulhall Christopher M. VP - Chief Accounting Officer | Tax withheld | 340 | $20.1K |
| Feb 27, 2026 | Underwood Peter C SVP - Chief Legal Officer | Tax withheld | 4,514 | $267.2K |
| Feb 24, 2026 | Underwood Peter C SVP - Chief Legal Officer | Tax withheld | 6,339 | $365.6K |
| Feb 24, 2026 | Soroye Olumide President & CEO | Tax withheld | 16,092 | $928.2K |
| Feb 24, 2026 | Underwood Peter C SVP - Chief Legal Officer | Award | 1,383 | — |
| Feb 24, 2026 | Soroye Olumide President & CEO | Award | 3,759 | — |
| Feb 24, 2026 | Okerstrom Mark D SVP - Chief Financial Officer | Award | 2,749 | — |
| Feb 18, 2026 | MITCHELL KATE Director | Option exercise | 7,131 | $210.9K |
| Feb 18, 2026 | MITCHELL KATE Director | Sale | 7,131 | $416.0K |
| Dec 26, 2025 | Lassiter Wright III Director | Code L | 5 | $257 |
| Nov 10, 2025 | Underwood Peter C SVP - Chief Legal Officer | Option exercise | 58,133 | $1.68M |
| Nov 10, 2025 | Underwood Peter C SVP - Chief Legal Officer | Sale | 58,133 | $2.98M |
| Oct 31, 2025 | Walker Stacey A. SVP - Chief People Officer | Sale | 2,192 | $110.4K |
| Aug 25, 2025 | Soroye Olumide President & CEO | Tax withheld | 13,280 | $644.2K |
| Aug 1, 2025 | Okerstrom Mark D Chief Financial Officer | Purchase | 21,300 | $1.00M |
| Jul 2, 2025 | Soroye Olumide President & CEO | Award | 18,915 | $1.01M |
| Jul 2, 2025 | Soroye Olumide President & CEO | Award | 14,185 | $756.6K |
| Jun 27, 2025 | Soroye Olumide President & CEO of AHS and IOS | Award | 21,856 | — |
| Jun 27, 2025 | Newcombe Tamara S. President & CEO of PT | Award | 3,562 | — |
| Jun 27, 2025 | Newcombe Tamara S. President & CEO of PT | Award | 17,485 | — |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Fortive Corp
Free account. Everything above stays public.
Write why you follow Fortive Corp and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading